ERBB2 and breast carcinoma: In their recent meta-analysis considering SPARC expression and prognosis in breast cancer, Shi et al. [57] showed that low SPARC expression correlated with worse overall and distant metastasis survival rates in grade 1/2 tumors, HER2-positive tumors, and luminal A subtype tumors.